Neurodegenerative diseases affect more than 57 million people globally. The incidence of these diseases, from Alzheimer's to Parkinson's to ALS and beyond, is expected to double every 20 years.

Proteomics technologies are expanding rapidly due to advances in mass spectrometry, AI-driven analysis, and single-cell approaches. Growing investment and new applications in drug discovery and ...

Using single-cell sequencing, researchers found distinct immune profiles in different CNS tumors, highlighting its potential as a prognostic tool.

Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

The iGE3 Genomics Platform provides access to the state-of-the-art methods in genomic technologies. Our platform provides a seamless, end-to-end solution tailored to your research needs. From ...